NASDAQ · HCWB
Healthcare · Biotechnology
$2.94
Up+$0.07 (+2.44%)
Updated Sep 6, 2026, 11:17 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
HCWB closed at $2.94 after 20 trading sessions, down 10.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $2.81 | $2.97 | $2.80 | $2.94 | 37.3K |
| Sep 3, 2026 | $3.34 | $3.34 | $2.7001 | $2.87 | 127.59K |
| Sep 2, 2026 | $3.54 | $3.81 | $3.32 | $3.355 | 210.75K |
| Sep 1, 2026 | $3.51 | $3.73 | $3.30 | $3.45 | 545.88K |
| Aug 31, 2026 | $3.60 | $3.60 | $3.2105 | $3.59 | 59.02K |
| Aug 28, 2026 | $3.20 | $3.43 | $3.00 | $3.43 | 127.56K |
| Aug 27, 2026 | $2.70 | $3.28 | $2.60 | $3.17 | 337.62K |
| Aug 26, 2026 | $2.69 | $2.70 | $2.55 | $2.70 | 62.39K |
| Aug 25, 2026 | $2.31 | $2.8881 | $2.28 | $2.60 | 281.82K |
| Aug 24, 2026 | $2.32 | $2.3233 | $2.15 | $2.31 | 308.04K |
| Aug 21, 2026 | $2.16 | $2.23 | $2.05 | $2.18 | 55.86K |
| Aug 20, 2026 | $2.26 | $2.38 | $2.06 | $2.12 | 90.09K |
| Aug 19, 2026 | $2.14 | $2.3999 | $2.13 | $2.30 | 111.86K |
| Aug 18, 2026 | $2.52 | $3.05 | $2.05 | $2.13 | 1.24M |
| Aug 17, 2026 | $2.68 | $2.8961 | $2.47 | $2.52 | 59.93K |
| Aug 14, 2026 | $3.1853 | $3.25 | $2.5801 | $2.68 | 130.4K |
| Aug 13, 2026 | $3.08 | $3.27 | $2.85 | $2.925 | 52.53K |
| Aug 12, 2026 | $3.21 | $3.3014 | $3.0901 | $3.145 | 55.92K |
| Aug 11, 2026 | $3.30 | $3.43 | $3.13 | $3.17 | 25.83K |
| Aug 10, 2026 | $3.44 | $3.67 | $3.24 | $3.27 | 39.28K |
The latest Smart Investors Daily articles mentioning HCWB.
HCWB research
Company profile and research snapshot.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 28, 2026 | Maxim Group | Buy | — |
| May 29, 2025 | Maxim Group | Buy | — |
| Apr 19, 2023 | EF Hutton | Buy | — |
| Mar 30, 2023 | EF Hutton | Buy | — |
| Mar 23, 2023 | EF Hutton | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 25, 2026
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune
Benzinga · Aug 18, 2026
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. The company's, Q2 earnings came
Benzinga · Aug 14, 2026
https://journals.asm.org/doi/full/10.1128/jvi.00051-26
Benzinga · Aug 14, 2026
On August 10, 2026, the Audit Committee of the Board of Directors (the "Audit Committee") of HCW Biologics Inc. (the "Company"), in consultation with management and the Company’s independent registered
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HCWB.
